NEJM Publishes Phase III ALLEGORY Results Showing Gazyva Reduces Disease Activity in Common Lupus
Genentech, a member of the Roche Group, has announced that detailed results from the Phase III ALLEGORY clinical trial evaluating Gazyva (obinutuzumab) in adults with Systemic Lupus Erythematosus (SLE) have been published in the The New England Journal of Medicine. The findings reveal that the therapy delivered statistically significant and clinically meaningful improvements in disease activity for patients living with the chronic autoimmune condition. The same data are also being presented at European Lupus Meeting SLEuro 2026, highlighting growing scientific interest in the treatment’s potential impact.
Strong Primary Endpoint Results
The Phase III ALLEGORY study evaluated the efficacy of Gazyva when used alongside standard therapy compared with placebo plus standard therapy. Results showed that 76.7% of patients receiving Gazyva achieved at least a four-point improvement in the SLE Responder Index 4 (SRI-4) after 52 weeks of treatment. In comparison, 53.5% of patients in the placebo group reached the same benchmark.
This translated into an adjusted difference of 23.1% between the treatment and placebo groups, with a 95% confidence interval ranging from 12.5 to 33.6 and a highly significant p-value of less than 0.001. These findings indicate that adding Gazyva to standard lupus therapy can significantly improve clinical outcomes and reduce disease activity.
Improvements Across Secondary Endpoints
Beyond meeting the primary endpoint, Gazyva also demonstrated superiority over placebo across every key and additional secondary endpoint evaluated in the study. One of the most notable improvements involved the time to the first disease flare—episodes of increased disease activity that can lead to irreversible organ damage in lupus patients.
Using the British Isles Lupus Assessment Group (BILAG) index to measure flare activity, the median time to first flare could not be estimated in the Gazyva group because many patients did not experience a flare during the study period. In contrast, the median time to flare in the placebo group was 52.3 weeks. This corresponded to a hazard ratio of 0.58, meaning that patients treated with Gazyva had a 42% lower risk of experiencing a flare during the study.
The therapy also showed a remarkable increase in remission rates. By week 52, 35.1% of patients receiving Gazyva achieved remission based on the Definition of Remission in SLE (DORIS) criteria, compared with just 13.8% of those receiving placebo. This represents an adjusted difference of 21.2%, demonstrating the therapy’s ability to drive deeper disease control.
Key Secondary Endpoint Outcomes
The trial met all five key secondary endpoints, further supporting the drug’s effectiveness in improving disease management for lupus patients.
Among these outcomes, the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response rate at 52 weeks was significantly higher in patients treated with Gazyva. Approximately 62.0% of patients receiving the therapy achieved a BICLA response, compared with 40.1% in the placebo group, representing an adjusted difference of 21.9%.
Steroid reduction—an important treatment goal due to the long-term side effects of corticosteroids—was another significant finding. Around 80% of patients receiving Gazyva were able to reduce their glucocorticoid dose to 7.5 mg per day or less and maintain this level between weeks 40 and 52. In comparison, only 54.1% of patients in the placebo group achieved the same reduction.
Additional measures of disease activity also showed meaningful improvements. Sustained SRI-4 responses from week 40 to week 52 occurred in 72.0% of Gazyva-treated patients versus 46.4% of those receiving placebo. Meanwhile, the stricter SRI-6 response at week 52 was achieved by 68.9% of patients receiving Gazyva compared with 38.9% in the control group.
Additional Measures of Disease Control
The study also evaluated broader measures of disease activity and remission.
At week 52, 57.6% of patients receiving Gazyva achieved Lupus Low Disease Activity State (LLDAS), compared with 25.0% of those receiving placebo. Achieving LLDAS is considered an important milestone for patients because it is associated with fewer disease flares and reduced long-term organ damage.
Together, these outcomes demonstrate the therapy’s ability to provide sustained disease control across multiple clinically relevant measures.
Expert Perspective on the Findings
According to Richard Furie, chief of the Division of Rheumatology at Northwell Health and professor at the Feinstein Institutes for Medical Research, the ALLEGORY study represents a major development in lupus research.
He noted that the findings provide compelling evidence that targeting B cells—a key driver of autoimmune disease—can significantly reduce disease activity in systemic lupus erythematosus. The results also suggest that patients may achieve more durable disease control with reduced reliance on steroids, which have historically been a cornerstone of lupus treatment but are associated with long-term side effects.
Dr. Furie emphasized that these advances could have meaningful implications not only for patients but also for physicians and families managing the disease, marking an important milestone in the evolution of lupus treatment strategies.
Company Perspective on the Results
Levi Garraway, chief medical officer and head of Global Product Development at Genentech, highlighted the longstanding challenges faced by people living with SLE.
For decades, patients have had to cope with unpredictable disease activity, limited therapeutic options, and significant steroid exposure. According to Garraway, the ALLEGORY trial demonstrates that Gazyva can deliver clinically meaningful and sustained disease control, which is crucial for preventing serious complications involving vital organs.
He added that the company plans to work closely with global regulatory authorities to make the treatment available to lupus patients as quickly as possible.
Regulatory Discussions Underway
Genentech confirmed that it is currently discussing the ALLEGORY data with regulatory agencies including the U.S. Food and Drug Administration and the European Medicines Agency.
If approved for SLE, Gazyva would become the first Type II anti-CD20 therapy specifically targeting B cells in this disease. B cells play a central role in lupus by producing autoantibodies that attack the body’s own tissues, leading to widespread inflammation and organ damage.
The safety results observed in the ALLEGORY study were consistent with the previously established safety profile of Gazyva. Importantly, investigators did not identify any new safety signals during the trial.
This reinforces the therapy’s existing clinical experience, particularly from its use in other indications and immune-mediated diseases.
The Global Burden of Lupus
Systemic lupus erythematosus affects more than three million people worldwide. The disease disproportionately affects women, particularly those between the ages of 15 and 45. Women of color are also affected at higher rates and often experience more severe disease.
SLE is characterized by recurring flares of inflammation that can damage multiple organs, including the kidneys, heart, skin, and nervous system. Approximately half of all patients develop lupus nephritis—a serious kidney complication—within five years of diagnosis.
Effective disease control is therefore essential for reducing flares, preventing irreversible organ damage, and lowering the risk of severe complications.
Expanding Evidence for Gazyva in Immune-Mediated Diseases
The ALLEGORY study represents one of four successful Phase III trials evaluating Gazyva in immune-mediated diseases. Other positive studies include:
- REGENCY clinical trial in lupus nephritis
- INShore clinical trial in idiopathic nephrotic syndrome
- MAJESTY clinical trial in primary membranous nephropathy
Together, these studies suggest that Gazyva may have a broader role in treating immune-driven diseases affecting the kidneys and other organs.
Current Approvals and Future Research
Gazyva is already approved in the United States and the European Union for the treatment of adults with active lupus nephritis based on data from the REGENCY and NOBILITY studies. In addition, the therapy is currently being evaluated in a global Phase II study involving children and adolescents with lupus nephritis.
Genentech and Roche are continuing to advance a broad immunology pipeline focused on immune-mediated kidney diseases and rheumatological disorders. The companies aim to expand treatment options for patients with autoimmune conditions where unmet medical needs remain significant.
With the ALLEGORY trial results now published and under regulatory review, Gazyva could potentially become a new therapeutic option for patients with systemic lupus erythematosus, offering the promise of better disease control and improved long-term outcomes.
Source Link: https://www.businesswire.com/
